NEW YORK (GenomeWeb) – Investment bank Janney upgraded Foundational Medicine to Neutral from Sell today, citing a recent rebound in the company's shares which analyst Paul Knight attributed to an expected easy sequential earnings comparison for the company in the first quarter, among other reasons.

Earlier this month, Foundation Medicine announced that it had received the first payment from Palmetto GBA — its Medicare Administrative Contractor in North Carolina — for the Foundation One genomic profiling assay for Stage IIIB/IV non-small cell lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.